besthealtharticle.com
Home »
The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death, when compared with rituximab plus placebo in a phase 3 trial of patients with relapsed, indolent non-Hodgkin lymphoma (NHL). The trial, dubbed CHRONOS-3, is the first to report “a broad benefit” across histologic subtypes of relapsed, indolent […]
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. An independent data monitoring committee is recommending stopping enrollment of a phase 3 trial of a monoclonal antibody for COVID-19 because interim results indicate an 85% (P = .002) reduction in hospitalizations or death, two companies have announced. Vir Biotechnology and […]
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how […]
(HealthDay)—Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England Journal of Medicine. Franck Morschhauser, M.D., Ph.D., from the University of Lille in France, and colleagues conducted an international, randomized phase 3 trial to […]